PURPOSE: Imatinib mesylate (Imatinib), clinically employed for chronic myeloid leukemia and gastrointestinal stromal tumors, is a selective inhibitor of the tyrosine kinases, c-abl, c-kit and PDGFRs. Due to the frequent expression of these genes in breast cancer cells, the clinical efficacy of Imatinib has recently been investigated in patients with advanced and metastatic breast cancer. Here, we have studied the effects of Imatinib on human MA-11 breast carcinoma cells, expressing both c-abl and PDGFRbeta, in vitro and in mouse xenografts. METHODS: The effects of Imatinib mesylate on the human MA-11 breast carcinoma cell line were studied in vitro and in xenografts. RESULTS: Daily intraperitoneal treatment with 60 mg/kg Imatinib for 9 days of athymic nude mice pre-implanted subcutaneously with MA-11 cells did not result in an anti-tumor effect, but rather increased the take rate of 3 × 10(4) cells from 30.8 to 84.6% and caused the appearance of large abdominal masses in 30% of mice. To investigate the mechanism(s) of the observed effects of Imatinib on MA-11 tumors, we exposed the cells in vitro to Imatinib for 9 days. The surviving population, expanded in culture, showed increased motility and over-expressed a set of genes associated with aggressive behavior. Also, several genes belonging to the Wnt and the MAPK pathway were differentially expressed. In promoter activation assays, Imatinib increased the promoter activity driven by both Wnt and MAPK/ERK-1/2. CONCLUSIONS: Our data suggest caution in the clinical use of Imatinib in breast cancer patients; the comparison of Imatinib-surviving breast cancer cells with parental cells may help define the regulatory pathways involved in the increased malignancy of residual tumor cells that survive therapy, ultimately providing important therapeutic targets.
PURPOSE:Imatinib mesylate (Imatinib), clinically employed for chronic myeloid leukemia and gastrointestinal stromal tumors, is a selective inhibitor of the tyrosine kinases, c-abl, c-kit and PDGFRs. Due to the frequent expression of these genes in breast cancer cells, the clinical efficacy of Imatinib has recently been investigated in patients with advanced and metastatic breast cancer. Here, we have studied the effects of Imatinib on humanMA-11breast carcinoma cells, expressing both c-abl and PDGFRbeta, in vitro and in mouse xenografts. METHODS: The effects of Imatinib mesylate on the humanMA-11breast carcinoma cell line were studied in vitro and in xenografts. RESULTS: Daily intraperitoneal treatment with 60 mg/kg Imatinib for 9 days of athymic nude mice pre-implanted subcutaneously with MA-11 cells did not result in an anti-tumor effect, but rather increased the take rate of 3 × 10(4) cells from 30.8 to 84.6% and caused the appearance of large abdominal masses in 30% of mice. To investigate the mechanism(s) of the observed effects of Imatinib on MA-11tumors, we exposed the cells in vitro to Imatinib for 9 days. The surviving population, expanded in culture, showed increased motility and over-expressed a set of genes associated with aggressive behavior. Also, several genes belonging to the Wnt and the MAPK pathway were differentially expressed. In promoter activation assays, Imatinib increased the promoter activity driven by both Wnt and MAPK/ERK-1/2. CONCLUSIONS: Our data suggest caution in the clinical use of Imatinib in breast cancerpatients; the comparison of Imatinib-surviving breast cancer cells with parental cells may help define the regulatory pathways involved in the increased malignancy of residual tumor cells that survive therapy, ultimately providing important therapeutic targets.
Authors: Frédérique Souazé; Sandra Dupouy; Véronique Viardot-Foucault; Erik Bruyneel; Samir Attoub; Christian Gespach; Anne Gompel; Patricia Forgez Journal: Cancer Res Date: 2006-06-15 Impact factor: 12.701
Authors: Anna Maria Wolf; Dominik Wolf; Holger Rumpold; Susanne Ludwiczek; Barbara Enrich; Guenther Gastl; Guenter Weiss; Herbert Tilg Journal: Proc Natl Acad Sci U S A Date: 2005-09-08 Impact factor: 11.205
Authors: Germana Rappa; Javier Mercapide; Fabio Anzanello; Thuc T Le; Mary G Johlfs; Ronald R Fiscus; Michaela Wilsch-Bräuninger; Denis Corbeil; Aurelio Lorico Journal: Exp Cell Res Date: 2013-01-12 Impact factor: 3.905
Authors: Xiaoxian Li; Michael T Lewis; Jian Huang; Carolina Gutierrez; C Kent Osborne; Meng-Fen Wu; Susan G Hilsenbeck; Anne Pavlick; Xiaomei Zhang; Gary C Chamness; Helen Wong; Jeffrey Rosen; Jenny C Chang Journal: J Natl Cancer Inst Date: 2008-04-29 Impact factor: 13.506
Authors: Manran Liu; Mathew C Casimiro; Chenguang Wang; L Andrew Shirley; Xuanmao Jiao; Sanjay Katiyar; Xiaoming Ju; Zhiping Li; Zuoren Yu; Jie Zhou; Michael Johnson; Paolo Fortina; Terry Hyslop; Jolene J Windle; Richard G Pestell Journal: Proc Natl Acad Sci U S A Date: 2009-10-26 Impact factor: 11.205
Authors: Chevaun D Morrison; Tressa M Allington; Cheryl L Thompson; Hannah L Gilmore; Jenny C Chang; Ruth A Keri; William P Schiemann Journal: Oncotarget Date: 2016-11-08